Cost-effectiveness of a new rotavirus vaccination program in Pakistan: A decision tree model

Vaccine

Volumn 31, Issue 51, 2013, Pages 6072-6078

  Patel, Hiten D ^a,b   Roberts, Eric T ^b   Constenla, Dagna O ^b  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Cost effectiveness; Gastroenteritis; Pakistan; Rotavirus; Vaccination

Indexed keywords

ROTAVIRUS VACCINE;

ARTICLE; BIRTH; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEATH; DECISION TREE; DRUG COST; GASTROENTERITIS; HEALTH CARE SYSTEM; HEALTH IMPACT ASSESSMENT; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; OUTPATIENT CARE; PAKISTAN; PRIORITY JOURNAL; QUALITY OF LIFE; ROTAVIRUS INFECTION; VACCINATION;

COST-EFFECTIVENESS; DALYS; DISABILITY-ADJUSTED LIFE-YEARS; DPT3; EASTERN MEDITERRANEAN REGION; EMR; FINAL DOSE OF DIPHTHERIA, PERTUSSIS, AND TETANUS VACCINATION; GASTROENTERITIS; GAVI; GDP; GLOBAL ALLIANCE FOR VACCINES AND IMMUNIZATION; GROSS DOMESTIC PRODUCT; ICER; INCREMENTAL COST-EFFECTIVENESS RATIO; PAKISTAN; PATH; PROGRAM FOR APPROPRIATE TECHNOLOGY IN HEALTH; ROTAVIRUS; ROTAVIRUS GASTROENTERITIS; RVGE; VACCINATION; WHO; WORLD HEALTH ORGANIZATION;

CHILD; CHILD, PRESCHOOL; COST-BENEFIT ANALYSIS; DECISION TREES; FEMALE; GASTROENTERITIS; HUMANS; IMMUNIZATION PROGRAMS; INFANT; INFANT, NEWBORN; MALE; PAKISTAN; ROTAVIRUS INFECTIONS; ROTAVIRUS VACCINES; VACCINATION;

EID: 84888440882     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.10.022     Document Type: Article

References (49)

1. Bryce J., Boschi-Pinto C., Shibuya K., Black R.E. WHO Child Health Epidemiology Reference Group. WHO estimates of the causes of death in children. Lancet 2005, 365:1147-1152.
2. Walker C.L., Rudan I., Liu L., Nair H., Theodoratou E., Bhutta Z.A., et al. Global burden of childhood pneumonia and diarrhoea. Lancet 2013, 381:1405-1416.
3. Tate J.E., Burton A.H., Boschi-Pinto C., Steele A.D., Duque J., Parashar U.D., et al. 2008 estimate of worldwide rotavirus-associated mortality in children younger than 5 years before the introduction of universal rotavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis 2012, 12:136-141.
4. Kawai K., O'Brien M.A., Goveia M.G., Mast T.C., El Khoury A.C. Burden of rotavirus gastroenteritis and distribution of rotavirus strains in Asia: a systematic review. Vaccine 2012, 30:1244-1254.
5. Khattak T.A., Ali S., Safdar C.A., Aslam M.S. Frequency of rotavirus infection in children with acute diarrhea. Pakistan Armed Forces Med J 2011, 1. [accessed 31.01.13]. http://www.pafmj.org/showdetails.php%3Fid=427%26t=o.
6. Khan Z.T., Hayat A., Asim S., Ehsan I.A., Piracha U.G., Javed I., et al. Burden of rotavirus gastroenteritis in children less than 5 years of age in Rawalpindi, Pakistan. J Rawal Med Coll 2006, 10:61-65.
7. Podewils L.J., Antil L., Hummelman E., Bresee J., Parashar U.D., Rheingans R. Projected cost-effectiveness of rotavirus vaccination for children in Asia. J Infect Dis 2005, 192:S133-S145.
8. Kim S.Y., Sweet S., Slichter D., Goldie S.J. Health and economic impact of rotavirus vaccination in GAVI-eligible countries. BMC Public Health 2010, 10:253.
9. Parashar U.D., Burton A., Lanata C., Boschi-Pinto C., Shibuya K., Steele D., et al. Global mortality associated with rotavirus disease among children in 2004. J Infect Dis 2009, 200:S9-S15.
10. World Health Organization Rotavirus vaccines: an update. Wkly Epidemiol Rec 2009, 84:533-540.
11. Ruiz-Palacios G.M., Pérez-Schael I., Velázquez F.R., Abate H., Breuer T., Clemens S.C., et al. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med 2006, 354(1):11-22.
12. Vesikari T., Matson D.O., Dennehy P., Van Damme P., Santosham M., Rodriguez Z., et al. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med 2006, 354(1):23-33.
13. Soares-Weiser K., Maclehose H., Bergman H., Ben-Aharon I., Nagpal S., Goldberg E., et al. Vaccines for preventing rotavirus diarrhoea: vaccines in use. Cochrane Database Syst Rev 2012, 11:CD008521.
14. Phua K.B., Lim F.S., Lau Y.L., Nelson E.A., Huang L.M., Quak S.H., et al. Safety and efficacy of human rotavirus vaccine during the first 2 years of life in Asian infants: randomised, double-blind, controlled study. Vaccine 2009, 27:5936-5941.
15. Zaman K., Dang D.A., Victor J.C., Shin S., Yunus M., Dallas M.J., et al. Efficacy of pentavalent rotavirus vaccine against severe rotavirus gastroenteritis in infants in developing countries in Asia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 376:615-623.
16. NCT01199874 Immunogenicity of Rotavirus Vaccine 2013, http://clinicaltrials.gov/ct2/show/NCT01199874 [accessed 31.01.13].
17. GAVI Alliance secures lower price for rotavirus vaccine 2013, GAVI Alliance, http://www.gavialliance.org/library/news/press-releases/2012/gavi-secures-lower-price-rotavirus-vaccine/ [accessed 31.01.13].
18. Plosker G.L. Pharmacoeconomic spotlight on rotavirus vaccine RIX4414 (Rotarix™) in the prevention of rotavirus gastroenteritis in developing countries. Paediatr Drugs 2012, 14:429-433.
19. Rotavirus vaccine support 2013, GAVI Alliance, http://www.gavialliance.org/support/nvs/rotavirus/ [accessed 11.03.13].
20. Tate J.E., Chitambar S., Esposito D.H., Sarkar R., Gladstone B., Ramani S., et al. Disease and economic burden of rotavirus diarrhoea in India. Vaccine 2009, 27:F18-F24.
21. Rose J., Hawthorn R.L., Watts B., Singer M.E. Public health impact and cost effectiveness of mass vaccination with live attenuated human rotavirus vaccine (RIX4414) in India: model based analysis. BMJ 2009, 339:b3653.
22. Esposito D.H., Tate J.E., Kang G., Parashar U.D. Projected impact and cost-effectiveness of a rotavirus vaccination program in India, 2008. Clin Infect Dis 2011, 52:171-177.
23. Brenzel L., Sanderson C., Galayda V., Masud T., Hap I. Cost-effectiveness and Financial Consequences of New Vaccine Introduction in Pakistan. HNP Discussion Paper 2013, World Bank, http://siteresources.worldbank.org/HEALTHNUTRITIONANDPOPULATION/Resources/281627-1095698140167/VaccineIntroPakistan.pdf [Published online October 2011, accessed 24.02.13].
24. World population prospects: the 2010 revision. In United Nations; 2011.
25. WHO Member States Life Tables 2009. Global Health Observatory 2013, http://www.who.int/healthinfo/statistics/mortality_life_tables/en/ [accessed 01.03.13].
26. Qazi R., Sultana S., Sundar S., Warraich H., un-Nisa T., Rais A., et al. Population-based surveillance for severe rotavirus gastroenteritis in children in Karachi, Pakistan. Vaccine 2009, 27:F25-F30.
27. Banerjee I., Ramani S., Primrose B., Moses P., Iturriza-Gomara M., Gray J.J., et al. Comparative study of the epidemiology of rotavirus in children from a community-based birth cohort and a hospital in South India. J Clin Microbiol 2006, 44:2468-2474.
28. Kosek M., Bern C., Guerrant R.L. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ 2003, 81:197-204.
29. Parashar U.D., Hummelman E.G., Bresee J.S., Miller M.A., Glass R.I. Global illness and deaths caused by rotavirus disease in children. Emerg Infect Dis 2003, 9:565-572.
30. O'Ryan M., Linhares A.C. Update on Rotarix: an oral human rotavirus vaccine. Expert Rev Vaccines 2009, 8:1627-1641.
31. Global Routine Vaccination Coverage, 2011. MMWR 2012, 61:883-885.
32. WHO Immunization profile-Pakistan 2010, WHO, Geneva, http://apps.who.int/immunization_monitoring/en/globalsummary/countryprofileselect.cfm [accessed 01.03.13].
33. de Oliveira L.H., Danovaro-Holliday M.C., Matus C.R., Andrus J.K. Rotavirus vaccine introduction in the Americas: progress and lessons learned. Expert Rev Vaccines 2008, 7:345-353.
34. Wolfson L.J., Gasse F., Lee-Martin S.P., Lydon P., Magan A., Tibouti A., et al. Estimating the costs of achieving the WHO-UNICEF Global Immunization Vision and Strategy, 2006-2015. Bull World Health Organ 2008, 86:27-39.
35. WHO-CHOICE (Choosing Interventions that are Cost-Effective) health care services unit cost database 2013, http://www.who.int/choice/country/country_specific/en/index.html [accessed 31.01.13].
36. Wildi-Runge S., Allemann S., Schaad U.B., Heininger U. A 4-year study on clinical characteristics of children hospitalized with rotavirus gastroenteritis. Eur J Pediatr 2009, 168:1343-1348.
37. Salomon J.A., Vos T., Hogan D.R., Gagnon M., Naghavi M., Mokdad A., et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012, 380:2129-2143.
38. Erdoǧan O., Tanyeri B., Torun E., Gönüllü E., Arslan H., Erenberk U., et al. The comparison of the efficacy of two different probiotics in rotavirus gastroenteritis in children. J Trop Med 2012, 2012:787240.
39. Kang G., Arora R., Chitambar S.D., Deshpande J., Gupte M.D., Kulkarni M., et al. Multicenter, hospitalbased surveillance of rotavirus disease and strains among Indian children aged <5 years. J Infect Dis 2009, 200:S147-S153.
40. Tan-Torres Edejer T., Baltussen R., Adam T., Hutubessy R., Acharya A., Evans D.B., et al. Making choices in health: WHO guide to cost-effectiveness analysis 2003, World Health Organization, Geneva.
41. Rodrigues A., de Carvalho M., Monteiro S., Mikkelsen C.S., Aaby P., Molbak K., et al. Hospital surveillance of rotavirus infection and nosocomial transmission of rotavirus disease among children in Guinea-Bissau. Pediatr Infect Dis J 2007, 26:233-237.
42. Soriano-Gabarró M., Mrukowicz J., Vesikari T., Verstraeten T. Burden of rotavirus disease in European Union countries. Pediatr Infect Dis J 2006, 25:S7-S11.
43. National Accounts Main Aggregates Database. United Nations 2013, http://unstats.un.org/unsd/snaama/selbasicFast.asp [accessed 31.01.13].
44. Cook J., Jeuland M., Whittington D., Poulos C., Clemens J., Sur D., et al. The cost-effectiveness of typhoid Vi vaccination programs: calculations for four urban sites in four Asian countries. Vaccine 2008, 26:6305-6316.
45. Griffiths U.K., Wolfson L.J., Quddus A., Younus M., Hafiz R.A. Incremental cost-effectiveness of supplementary immunization activities to prevent neonatal tetanus in Pakistan. Bull World Health Organ 2004, 82:643-651.
46. Khan M.A., Walley J.D., Witter S.N., Imran A., Safdar N. Costs and cost-effectiveness of different DOT strategies for the treatment of tuberculosis in Pakistan. Directly Observed Treatment. Health Policy Plan 2002, 17:178-186.
47. Jafar T.H., Islam M., Bux R., Poulter N., Hatcher J., Chaturvedi N., et al. Cost-effectiveness of community-based strategies for blood pressure control in a low-income developing country: findings from a cluster-randomized, factorial-controlled trial. Circulation 2011, 124:1615-1625.
48. Wolfson L.J., Grais R.F., Luquero F.J., Birmingham M.E., Strebel P.M. Estimates of measles case fatality ratios: a comprehensive review of community-based studies. Int J Epidemiol 2009, 38:192-205.
49. Velázquez F.R., Matson D.O., Calva J.J., Guerrero L., Morrow A.L., Carter-Campbell S., et al. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med 1996, 335:1022-1028.